1. Home
  2. OFG vs ARDX Comparison

OFG vs ARDX Comparison

Compare OFG & ARDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo OFG Bancorp

OFG

OFG Bancorp

HOLD

Current Price

$42.12

Market Cap

1.6B

Sector

Finance

ML Signal

HOLD

Logo Ardelyx Inc.

ARDX

Ardelyx Inc.

HOLD

Current Price

$6.74

Market Cap

1.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
OFG
ARDX
Founded
1964
2007
Country
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.6B
1.6B
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
OFG
ARDX
Price
$42.12
$6.74
Analyst Decision
Buy
Strong Buy
Analyst Count
5
10
Target Price
$43.40
$12.95
AVG Volume (30 Days)
416.9K
4.0M
Earning Date
01-01-0001
01-01-0001
Dividend Yield
3.32%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$10.14
$22.44
Revenue Next Year
$1.38
$34.00
P/E Ratio
$9.21
N/A
Revenue Growth
N/A
N/A
52 Week Low
$33.15
$3.21
52 Week High
$46.11
$8.40

Technical Indicators

Market Signals
Indicator
OFG
ARDX
Relative Strength Index (RSI) 58.43 42.01
Support Level $41.27 $6.92
Resistance Level $42.53 $7.43
Average True Range (ATR) 1.01 0.31
MACD 0.23 -0.15
Stochastic Oscillator 85.51 7.30

Price Performance

Historical Comparison
OFG
ARDX

About OFG OFG Bancorp

OFG Bancorp is a financial holding company, through its subsidiaries provides banking and financial services. It operates through three segments namely Banking, Wealth Management, and Treasury. It serves to clients such as commercial, consumer, auto, and mortgage lending, checking and savings accounts, financial planning, insurance, financial services, and investment brokerage, and corporate and individual trust and retirement services. The company derives maximum revenue from Banking Segment. It provides services in the region of Puerto Rico.

About ARDX Ardelyx Inc.

Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. It product Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.

Share on Social Networks: